Pacira BioSciences (NASDAQ:PCRX) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Pacira BioSciences (NASDAQ:PCRX) from a strong-buy rating to a buy rating in a report published on Saturday.

A number of other brokerages also recently weighed in on PCRX. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Barclays began coverage on Pacira BioSciences in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 target price for the company. Finally, Truist Financial decreased their price target on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $30.75.

Pacira BioSciences Trading Down 3.0%

Shares of Pacira BioSciences stock opened at $21.91 on Friday. The company has a quick ratio of 3.78, a current ratio of 5.26 and a debt-to-equity ratio of 0.52. Pacira BioSciences has a 12-month low of $18.80 and a 12-month high of $27.64. The company has a market capitalization of $942.57 million, a price-to-earnings ratio of 146.07 and a beta of 0.24. The firm’s 50-day moving average price is $22.65 and its two-hundred day moving average price is $23.84.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.57 earnings per share for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The firm had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a return on equity of 10.16% and a net margin of 0.97%.The business’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $0.91 EPS. On average, analysts forecast that Pacira BioSciences will post 2.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Pacira BioSciences

In other news, SVP Lauren Riker sold 4,000 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the sale, the senior vice president owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. This represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Shawn Cross sold 9,104 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $25.14, for a total value of $228,874.56. Following the transaction, the chief financial officer owned 56,250 shares of the company’s stock, valued at $1,414,125. This trade represents a 13.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 30,416 shares of company stock worth $744,315. 6.40% of the stock is currently owned by insiders.

Institutional Trading of Pacira BioSciences

Several institutional investors have recently added to or reduced their stakes in PCRX. Hussman Strategic Advisors Inc. bought a new position in shares of Pacira BioSciences during the 3rd quarter worth about $2,706,000. Doma Perpetual Capital Management LLC raised its stake in Pacira BioSciences by 49.7% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock worth $69,613,000 after buying an additional 897,255 shares during the period. Exchange Traded Concepts LLC acquired a new stake in Pacira BioSciences in the third quarter valued at approximately $1,948,000. Impax Asset Management Group plc increased its holdings in shares of Pacira BioSciences by 27.7% during the third quarter. Impax Asset Management Group plc now owns 600,027 shares of the company’s stock valued at $15,463,000 after acquiring an additional 130,000 shares in the last quarter. Finally, American Century Companies Inc. raised its position in shares of Pacira BioSciences by 77.2% during the second quarter. American Century Companies Inc. now owns 1,182,513 shares of the company’s stock worth $28,262,000 after purchasing an additional 515,090 shares during the period. 99.73% of the stock is currently owned by institutional investors.

More Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.